Literature DB >> 29404958

Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer's Disease.

Miren Ettcheto1,2,3,4, Elena Sánchez-López2,5,6, Yaiza Gómez-Mínguez1, Henrry Cabrera1, Oriol Busquets1,2,3,4, Carlos Beas-Zarate7, Maria Luisa García5,6, Eva Carro8, Gemma Casadesus9, Carme Auladell10, Manuel Vázquez Carrera1,11,12,13, Jaume Folch2,3, Antoni Camins14,15,16.   

Abstract

There is growing evidence that obesity associated with type 2 diabetes mellitus (T2DM) and aging are risk factors for the development of Alzheimer's disease (AD). However, the molecular mechanisms through which obesity interacts with β-amyloid (Aβ) to promote cognitive decline remains poorly understood. Memantine (MEM), a N-methyl-D-aspartate receptor antagonist, is currently used for the treatment of AD. Nonetheless, few studies have reported its effects on genetic preclinical models of this neurodegenerative disease exacerbated with high-fat diet (HFD)-induced obesity. Therefore, the present research aims to elucidate the effects of MEM on familial AD HFD-induced insulin resistance and learning and memory impairment. Furthermore, it aspires to determine the possible underlying mechanisms that connect AD to T2DM. Wild type and APPswe/PS1dE9 mice were used in this study. The animals were fed with either chow or HFD until 6 months of age, and they were treated with MEM-supplemented water (30 mg/kg) during the last 12 weeks. Our study demonstrates that MEM improves the metabolic consequences produced by HFD in this model of familial AD. Behavioural assessments confirmed that the treatment also improves animals learning abilities and decreases memory loss. Moreover, MEM treatment improves brain insulin signalling upregulating AKT, as well as cyclic adenosine monophosphate response element binding (CREB) expression, and modulates the amyloidogenic pathway, which, in turn, reduced the accumulation of Aβ. Moreover, this drug increases the activation of molecules involved with insulin signalling in the liver, such as insulin receptor substrate 2 (IRS2), which is a key protein regulating hepatic resistance to insulin. These results provide new insight into the role of MEM not only in the occurrence of AD treatment, but also in its potential application on peripheral metabolic disorders where Aβ plays a key role, as is the case of T2DM.

Entities:  

Keywords:  APPswe/PS1dE9; Alzheimer’s disease; Diabetes; High-fat diet; Memantine; Obesity

Mesh:

Substances:

Year:  2018        PMID: 29404958     DOI: 10.1007/s12035-018-0868-4

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  54 in total

1.  A Key Role of Insulin Receptors in Memory.

Authors:  Fernanda G De Felice; Christian Benedict
Journal:  Diabetes       Date:  2015-11       Impact factor: 9.461

2.  Gender differences of peripheral plasma and liver metabolic profiling in APP/PS1 transgenic AD mice.

Authors:  Junfang Wu; Bin Fu; Hehua Lei; Huiru Tang; Yulan Wang
Journal:  Neuroscience       Date:  2016-07-05       Impact factor: 3.590

3.  Diabetes, obesity, and the brain.

Authors:  Michael W Schwartz; Daniel Porte
Journal:  Science       Date:  2005-01-21       Impact factor: 47.728

4.  Beta cell glutamate receptor antagonists: novel oral antidiabetic drugs?

Authors:  Claes B Wollheim; Pierre Maechler
Journal:  Nat Med       Date:  2015-04       Impact factor: 53.440

5.  Insulin potentiates the therapeutic effect of memantine against central STZ-induced spatial learning and memory deficit.

Authors:  Abbas Bahramian; Karim Rastegar; Mohammad Reza Namavar; Maryam Moosavi
Journal:  Behav Brain Res       Date:  2016-05-24       Impact factor: 3.332

Review 6.  Hippocampal insulin resistance and cognitive dysfunction.

Authors:  Geert Jan Biessels; Lawrence P Reagan
Journal:  Nat Rev Neurosci       Date:  2015-10-14       Impact factor: 34.870

Review 7.  IRS2 and PTP1B: Two opposite modulators of hepatic insulin signalling.

Authors:  Angela M Valverde; Agueda González-Rodríguez
Journal:  Arch Physiol Biochem       Date:  2011-03-14       Impact factor: 4.076

Review 8.  Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis.

Authors:  Kirsten L Viola; William L Klein
Journal:  Acta Neuropathol       Date:  2015-01-22       Impact factor: 17.088

Review 9.  Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease.

Authors:  Suzanne M de la Monte; Jack R Wands
Journal:  J Alzheimers Dis       Date:  2005-02       Impact factor: 4.472

Review 10.  Is Alzheimer's disease a systemic disease?

Authors:  Jill K Morris; Robyn A Honea; Eric D Vidoni; Russell H Swerdlow; Jeffrey M Burns
Journal:  Biochim Biophys Acta       Date:  2014-04-18
View more
  10 in total

1.  Diet-induced insulin resistance elevates hippocampal glutamate as well as VGLUT1 and GFAP expression in AβPP/PS1 mice.

Authors:  Erin R Hascup; Sarah O Broderick; Mary K Russell; Yimin Fang; Andrzej Bartke; Heather A Boger; Kevin N Hascup
Journal:  J Neurochem       Date:  2019-01-03       Impact factor: 5.372

2.  Memantine, a Noncompetitive N-Methyl-D-Aspartate Receptor Antagonist, Attenuates Cerebral Amyloid Angiopathy by Increasing Insulin-Degrading Enzyme Expression.

Authors:  Yasuteru Inoue; Mitsuharu Ueda; Teruaki Masuda; Yohei Misumi; Taro Yamashita; Yukio Ando
Journal:  Mol Neurobiol       Date:  2019-07-06       Impact factor: 5.590

3.  Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APPswe/PS1dE9 Mice.

Authors:  Miren Ettcheto; Amanda Cano; Patricia R Manzine; Oriol Busquets; Ester Verdaguer; Rubén Dario Castro-Torres; Maria Luisa García; Carlos Beas-Zarate; Jordi Olloquequi; Carme Auladell; Jaume Folch; Antoni Camins
Journal:  Mol Neurobiol       Date:  2019-12-14       Impact factor: 5.590

4.  Transcriptomic signatures of treatment response to the combination of escitalopram and memantine or placebo in late-life depression.

Authors:  Adrienne Grzenda; Prabha Siddarth; Kelsey T Laird; Jillian Yeargin; Helen Lavretsky
Journal:  Mol Psychiatry       Date:  2020-05-07       Impact factor: 15.992

Review 5.  Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings.

Authors:  Pallavi Duggal; Sidharth Mehan
Journal:  J Alzheimers Dis Rep       Date:  2019-07-02

6.  Aging Reduces Estradiol Protection Against Neural but Not Metabolic Effects of Obesity in Female 3xTg-AD Mice.

Authors:  Amy Christensen; Jiahui Liu; Christian J Pike
Journal:  Front Aging Neurosci       Date:  2020-05-05       Impact factor: 5.750

7.  Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer's disease in metabolically stressed APPswe/PS1dE9 mice.

Authors:  Miren Ettcheto; Elena Sánchez-Lopez; Amanda Cano; Marina Carrasco; Katherine Herrera; Patricia R Manzine; Triana Espinosa-Jimenez; Oriol Busquets; Ester Verdaguer; Jordi Olloquequi; Carme Auladell; Jaume Folch; Antoni Camins
Journal:  Cell Biosci       Date:  2021-07-22       Impact factor: 7.133

8.  High-Fat Diet Increases Amylin Accumulation in the Hippocampus and Accelerates Brain Aging in hIAPP Transgenic Mice.

Authors:  Xiao-Xia Xi; Jing Sun; Hai-Chao Chen; An-Di Chen; Li-Ping Gao; Jie Yin; Yu-Hong Jing
Journal:  Front Aging Neurosci       Date:  2019-08-27       Impact factor: 5.750

9.  Anti-Amnesic and Neuroprotective Effects of Fluoroethylnormemantine in a Pharmacological Mouse Model of Alzheimer's Disease.

Authors:  Simon Couly; Morgane Denus; Mélanie Bouchet; Gilles Rubinstenn; Tangui Maurice
Journal:  Int J Neuropsychopharmacol       Date:  2021-02-15       Impact factor: 5.176

Review 10.  Metabolic Syndrome: Is It Time to Add the Central Nervous System?

Authors:  Milagros Rojas; Mervin Chávez-Castillo; Daniela Pirela; Heliana Parra; Manuel Nava; Maricarmen Chacín; Lissé Angarita; Roberto Añez; Juan Salazar; Rina Ortiz; Samuel Durán Agüero; Marbel Gravini-Donado; Valmore Bermúdez; Edgar Díaz-Camargo
Journal:  Nutrients       Date:  2021-06-30       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.